Cadence Pharmaceuticals Inc

Cadence Pharmaceuticals — Investor Presentation (May 2011)

26 slides from Cadence Pharmaceuticals's investor presentation, May 11, 2011

  1. Slide 1: Cadence Pharmaceuticals, Inc. Corporate Presentation

    Cadence Pharmaceuticals, Inc. Corporate Presentation Improving the lives of hospitalized patients May 11, 2011 Exhibit 99.1

  2. Slide 2: Forward-looking statements

    Forward-looking statements © 2011 Cadence Pharmaceuticals, Inc. All rights reserved. This presentation includes forward-looking statements, which are based on our current beliefs and expectations. Such statements include, without limitation, statements regarding: the anticipated U.S. market opportun

  3. Slide 3: Cadence: investment highlights

    Cadence: investment highlights Hospital-focused specialty pharmaceutical company OFIRMEV ® launched with broad pain and fever indication in January 2011 – Rapid formulary adoption demonstrated – Established hospital sales team provides a core platform for the acquisition of additional products – Man

  4. Slide 4: Product overview: OFIRMEV (acetaminophen) injection

    OFIRMEV ® : product overview OFIRMEV (acetaminophen) injection – Proprietary IV acetaminophen formulation – First and only IV formulation of acetaminophen approved in the United States – New class of IV medication • non-narcotic / opioid • non-NSAID – Same formulation of IV acetaminophen marketed by

  5. Slide 5: Indication supports message

    OFIRMEV ® : indication supports message Broad Indication • Mild to moderate pain • Moderate to severe pain with adjunctive opioids • Reduction of fever • Adults and children 2 and older Message • Significant pain relief • Reduced opioid consumption* • Improved patient satisfaction • Established safe

  6. Slide 6: Strong foundation for commercial success

    OFIRMEV ® : Effective Pain Control Experienced Hospital Sales Force Economic Value strong foundation for commercial success • Sales force average >10 years hospital selling experience • Extensive relationships, significant overlap with prior territory • Substantial hospital commercial experience thr

  7. Slide 7: Strong early launch indicators

    OFIRMEV ® : strong early launch indicators* Rapid formulary adoption – On formulary in 675 hospitals in first 15 weeks of launch – Mix of formulary wins is representative of overall target market – Includes major academic medical centers and large community healthcare systems Most hospitals approved

  8. Slide 8: Vial sales off to strong start

    OFIRMEV ® : vial sales off to strong start Vial* Sales of Comparable New Hospital Product Launches Over Last 5 Years 20,000 40,000 60,000 80,000 100,000 120,000 Month Post Launch OFIRMEV (1-11) TEFLARO (1-11) DORIBAX (10-07) CLEVIPREX (9-08) VAPRISOL (3-06) VIBATIV (10-09) LUSEDRA (11-09) ENTEREG (d

  9. Slide 9: Limitations of other IV pain therapies

    Limitations of other IV pain therapies Opioids NSAIDs Sedation Nausea Vomiting Constipation Headache Cognitive impairment Respiratory depression Black Box Warning Bleeding GI complications Kidney complications Cardiovascular risks Prolonged recovery Increased length of stay Higher costs to the insti

  10. Slide 10: Multi-modal analgesia: the norms

    Pain Intensity Current US Approach Current EU Approach Multi-modal analgesia: the norms Severe Opioids IV acetaminophen + opioids Moderate Opioids IV acetaminophen +/- opioids* Mild Opioids IV acetaminophen * First post operative analgesic drug, then add opioids if necessary

  11. Slide 11: Sinatra Study: pivotal acute pain clinical trial

    IV acetaminophen placebo p-value Sinatra Study: pivotal acute pain clinical trial IV acetaminophen placebo p-value Sinatra, et al. Anesthesiology, V 102, No. 4, April 2005. Weighted sums of pain relief over 6hrs 6.6 2.2 <0.05 Patient Satisfaction (Good/excellent – hrs) 41% 23% <0.01 Morphine consump

  12. Slide 12: Established safety profile

    OFIRMEV ® : established safety profile % of adult patients with AST/ALT elevations in five repeat-dose clinical trials IV APAP ( n=402) Placebo (n=379) ALT > 3x ULN > 5x ULN AST > 3x ULN > 5x ULN 1.1% (n=4) 0.3% (n=1) 1.7% (n=6) 0.6% (n=2) 1.0% (n=4) 0.5% (n=2) 1.1% (n=4) 0.8% (n=3) * Data from a po

  13. Slide 13: Consistent opioid reduction across studies

    Pain Intensity Opioid Reduction* Time p Value Consistent opioid reduction across studies Severe 33% 24h <0.01 61% 24h <0.05 Moderate 53% 0-6h 0.016 Mild 86% 24h <0.001 78% 24h <0.01 *Reduction in number of patients requiring analgesic rescue with ketorolac and fentanyl 1) Sinatra, et al, 2005; 2) Me

  14. Slide 14: IV acetaminophen: EU market leader

    IV acetaminophen: EU market leader Source: IMS Data *(SOM – Share of market) • >20% unit share of injectable analgesic market

  15. Slide 15: Europe: 78% receive IV acetaminophen post-op

    Europe: 78% receive IV acetaminophen post - op % of Inpatients Given Each of the Following Treatments Post-operatively PharmaSavvy market research 2009. n=60 anesthetists (commissioned by Cadence Pharmaceuticals)

  16. Slide 16: US: >70% may receive IV acetaminophen post-op

    US: >70% may receive IV acetaminophen post - op Post-op inpatient treatment assignments assuming availability of IV acetaminophen* (Product X) PharmaSavvy market research 2009. n=102 (52 surgeons, 50 anesthesiologists) * Based on target product profile similar to OFIRMEV™ approved indications

  17. Slide 17: Early adoption

    OFIRMEV ® : early adoption ATU Research 10/2010 Base: Anesthesiologists and surgeons Q55. How soon after FDA approval would you expect to first use Product X (IV acetaminophen)? Virtually all respondents expect to use OFIRMEV at some point. About half of respondents across specialties would expect t

  18. Slide 18: The UK experience: an appropriate model

    The UK experience: an appropriate model UK treatment paradigms for moderate and acute pain are similar to those in the US – Higher opioid than NSAID usage – Multimodal pain therapy Perfalgan, BMY’s IV acetaminophen – Launched in 2004 – Has taken approximately 35% market share – Most share taken from

  19. Slide 19: Oral opioids: acetaminophen combinations dominate

    Oral opioids: acetaminophen combinations dominate Opioid-acetaminophen combinations Opioid-only products Opioid-NSAID combinations 73% 25% 1% Source: IMS data, 2008. 73% of oral opioid doses sold in U.S. contain acetaminophen Approximately 14.4 billion total doses sold in 2008 Acetaminophen + hydroc

  20. Slide 20: US market opportunity

    OFIRMEV ® : US market opportunity US and EU injectable analgesics markets are similarly sized Approximately 87 million IV acetaminophen units sold in Europe in 2009 Continued EU market expansion after introduction of IV acetaminophen List price $10.75 per vial; net price approximately $10.05 per via

  21. Slide 21: Hospital products: multi-step launch process

    Hospital products: multi - step launch process Regulatory Approval Doctor Access Formulary Access

  22. Slide 22: Injectable analgesic market: highly concentrated

    Injectable analgesic market: highly concentrated Source: WoltersKluwer Non-Retail Outlet Data, June 2009 MAT *Injectable analgesics consist of USCs 02221, 02211, 02131, 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 1,000 2,000 3,000 4,000 5,000 6,000 Number of Hospitals The top 1,874 (28%) hospitals g

  23. Slide 23: Experienced, seasoned, tested sales organization

    Experienced, Seasoned, Tested Sales Organization 147 Hospital Sales Specialists – >10 years hospital selling experience – 90% resigned to join Cadence – Extensive relationships, 70% overlap with prior territory Deep hospital commercial experience – CEO > 25 years – CCO > 15 years – VP Sales > 25 yea

  24. Slide 24: Economic value

    OFIRMEV ® : economic value Placebo-controlled studies using IV acetaminophen demonstrated results that may be associated with possible hospital cost savings: – Decreased opioid consumption * • Total hip/knee replacement (1) • Total hip replacement (2, 3) • Adult tonsillectomy (4) • Endoscopic thyroi

  25. Slide 25: Cadence: financial position

    Cadence: financial position 12 Months Ended 12/31/10 (MM) 3 Months Ended 3/31/11 (MM) Operating expenses $ 54.9 $ 22.7 Cash, cash equivalents & short-term investments $134.1 $109.0 (1) Shares outstanding 63.1 63.3 (1) Does not include a $5.3 million upfront payment received in April 2011 under a dat

  26. Slide 26: Product overview

    OFIRMEV ® : product overview OFIRMEV (acetaminophen) injection – Proprietary IV acetaminophen formulation – First and only IV formulation of acetaminophen approved in the United States – New Class of IV Analgesic OFIRMEV launched with broad pain and fever indication in January 2011 – Rapid formulary

Cadence Pharmaceuticals — Investor Presentation (May 2011) on 6ix